John Forbes
Impact in
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Cancer Treatment and Pharmacology
Papers in
-
- Breast Cancer Treatment Studies 56
- Oncology 39
- Cancer Risks and Factors 11
- Cancer Treatment and Pharmacology 10
- HER2/EGFR in Cancer Research 8
- Co-authors
- Jack M. Cuzick (41 shared papers)Anthony Howell (28 shared papers)Mitch Dowsett (20 shared papers)Ivana Šestak (21 shared papers)Aman U. Buzdar (13 shared papers)Alan Stuart Coates (33 shared papers)Michael S. Baum (5 shared papers)Michael Baum (2 shared papers)
- Journals
- Journal of Clinical Oncology (30 papers)The Lancet (19 papers)Annals of Oncology (14 papers)The Lancet Oncology (11 papers)Breast Cancer Research and Treatment (10 papers)
- Partner nations
- United KingdomAustraliaUnited States
In The Last Decade
John Forbes
211 papers receiving 25.7k citations
John Forbes's Hit Papers
Peers
Comparison fields: 5 of 179
- Cancer Research 9.7k
- Oncology 9.2k
- Genetics 5.9k
- Family Practice 320
- Pulmonary and Respiratory Medicine 3.6k
Countries citing papers authored by John Forbes
This map shows the geographic impact of John Forbes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Forbes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Forbes more than expected).
Fields of papers citing papers by John Forbes
This network shows the impact of papers produced by John Forbes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Forbes. The network helps show where John Forbes may publish in the future.
Co-authors
The 25 scholars most cited alongside John Forbes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 214 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Hit paper breakdown → | 2013 | 2950 |
| 2 | Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Hit paper breakdown → | 2005 | 1871 |
| 3 | Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Hit paper breakdown → | 2012 | 1564 |
| 4 | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Hit paper breakdown → | 2010 | 1213 |
| 5 | Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials Hit paper breakdown → | 2017 | 844 |
| 6 | Overview of the main outcomes in breast-cancer prevention trials Hit paper breakdown → | 2003 | 770 |
| 7 | Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 Hit paper breakdown → | 2007 | 746 |
| 8 | Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Hit paper breakdown → | 2007 | 716 |
| 9 | Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen Hit paper breakdown → | 2009 | 652 |
| 10 | 2011 | 606 | |
| 11 | Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study Hit paper breakdown → | 2010 | 597 |
| 12 | Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial Hit paper breakdown → | 2013 | 483 |
| 13 | Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy Hit paper breakdown → | 2010 | 449 |
| 14 | 2016 | 440 | |
| 15 | 2010 | 432 | |
| 16 | Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy Hit paper breakdown → | 2015 | 430 |
| 17 | 2018 | 401 | |
| 18 | Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data Hit paper breakdown → | 2013 | 384 |
| 19 | Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants Hit paper breakdown → | 2020 | 382 |
| 20 | 2008 | 377 |
About John Forbes
John Forbes is a scholar working on Cancer Research, Oncology, Genetics, Rehabilitation and Pathology and Forensic Medicine, having authored 214 papers that have together received 26.9k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (56 papers), Estrogen and related hormone effects (25 papers), Cancer Risks and Factors (11 papers), Cancer Treatment and Pharmacology (10 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers), Advanced Breast Cancer Therapies (9 papers), Stroke Rehabilitation and Recovery (9 papers) and HER2/EGFR in Cancer Research (8 papers). The work is most often cited by research in Cancer Research (9.7k citations), Oncology (9.2k citations), Genetics (5.9k citations), Family Practice (320 citations) and Pulmonary and Respiratory Medicine (3.6k citations). John Forbes has collaborated with scholars based in United Kingdom, Australia and United States. Frequent co-authors include Jack M. Cuzick, Anthony Howell, Mitch Dowsett, Ivana Šestak, Aman U. Buzdar, Alan Stuart Coates, Michael S. Baum, Michael Baum, Aron Goldhirsch and G Hoctin-Boes. Their work appears in journals such as Journal of Clinical Oncology, The Lancet, Annals of Oncology, The Lancet Oncology and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.